Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Children With ADHD
NCT07717879Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solriamfetol in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Axsome Therapeutics, Inc. Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale 5 Total Score at 6 weeks. Started Jul 2026; status: recruiting.
02
Drugs
solriamfetol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07717879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717879.